The House Concurrent Resolution memorializes the United States Congress to prioritize and expedite research, clinical trials, and treatment development for Acute Myeloid Leukemia (AML), a rare and aggressive blood cancer with a low five-year survival rate of approximately thirty percent. The resolution highlights the urgent need for enhanced federal investment in early detection and innovative therapies, particularly in light of the rapid progression of AML, which can lead to life-threatening complications shortly after diagnosis. It also acknowledges the impact of environmental and occupational exposures on the risk of developing hematologic malignancies, including AML.

In honor of Jonas A. Feeley, who tragically passed away from AML just one day after his diagnosis, the resolution proposes that these federal efforts be collectively recognized as the "Jonas A. Feeley Act." The resolution aims to advocate for the health and welfare of individuals and families affected by AML and calls for the transmission of this resolution to key federal health officials and the Louisiana congressional delegation to ensure that the urgency of this matter is addressed.